Should we stop this whole life extension thing while we still can in order to prevent this potential problem? Yeah… no. Here’s why.
New interview with author and researcher Dr. Josh Mitteldorf who runs the aging research blog Aging Matters.
Interview with author and researcher Dr. Josh Mitteldorf who runs the aging research blog ‘Aging Matters’.
Dr. Josh Mitteldorf is an evolutionary biologist and a long-time contributor to the growing field of aging science. His work in this field has focused on theories of aging. He asks the basic question: why do we age and die?
Continue reading “Josh Mitteldorf — Cracking the Aging Code” »
Today, we have launched the MitoMouse project on our fundraising platform Lifespan.io. This project aims to reverse the damage that aging does to the mitochondrial DNA and to restore energy production in our cells with the goal of preventing age-related ill health.
The power stations of the cell
Continue reading “MitoMouse – Curing Mitochondrial Dysfunction in Mammals” »
From signing a nine-page consent form to spending hundreds of thousands of dollars, a woman has revealed what happens inside a cryonics lab.
???? Respect AEWR & r.p.berry
Scientists find promising results in trial to reverse biological aging.
A triple drug combination has been used to extend the lifespan of fruit flies by 48% in a new study led by UCL and the Max Planck Institute for Biology of Ageing.
The three drugs are all already in use as medical treatments: lithium as a mood stabiliser, trametinib as a cancer treatment and rapamycin as an immune system regulator.
The findings, published in Proceedings of the National Academy of Sciences (PNAS), suggest that a combination drug treatment may one day be helpful at preventing age-related diseases in people.
Click on photo to start video.
A follow on study from their previous human trial targeting IPF. This time the researchers ran a study to see how senolytics influenced diabetic kidney disease and if it actually removes senescent cells in humans.
Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with ageing and at etiological sites in multiple chronic diseases. Senolytics, including the combination of Dasatinib and Quercetin (D + Q), selectively eliminate senescent cells by transiently disabling pro-survival networks that defend them against their own apoptotic environment. In the first clinical trial of senolytics, D + Q improved physical function in patients with idiopathic pulmonary fibrosis (IPF), a fatal senescence-associated disease, but to date, no peer-reviewed study has directly demonstrated that senolytics decrease senescent cells in humans.
At our 2019 Ending Age-related Diseases conference in New York City, we had the pleasure of speaking with Dr. Michael West, the CEO of AgeX Therapeutics.
Dr. West can rightfully be called a pioneer in his field with a substantial background in biomedical and biotechnology corporations. After completing his PhD at Baylor College of Medicine, he founded Geron Corporation in 1990, where he launched and directed programs in telomere biology as it relates to cancer, aging, and human embryonic stem cell technology. He subsequently established the research group that went on to isolate human embryonic stem cells for the first time.
Humanity+ is the world’s largest transhumanist organization that advocates ethical use of technology and evidence-based science for radical life extension.
